No abstract

A compact low-temperature plasma jet device was developed to use ambient air as plasma gas. The device was driven by a 2.52-kV high-voltage direct-current pulse in a burst mode, with a repetition rate of 2 kHz. The maximum plasma discharge current was 3.5 A, with an approximately 10 ns full-width half-maximum. Nitric oxide, hydroxyl radical, atomic oxygen, ozone, and hydrogen peroxide—important reactive oxygen and nitrogen species (RONS)—were mainly produced. The amount of plasma-generated RONS can be controlled by varying the pulse-modulation factors. After optimization, the plasma plume length was approximately 5 mm and the treatment temperature was less than 40 °C. The preliminary bactericidal effects were tested on Staphylococcus aureus, Pseudomonas aeruginosa, and methicillin-resistant S. aureus (MRSA), and their biofilms. The results showed that the plasma can effectively inactivate S. aureus, P. aeruginosa, and MRSA in both time- and pulse-dependent manner. Thus, this produced plasma device proved to be an efficient tool for inactivating deteriorating bacteria. Further versatile utilization of this portable plasma generator is also promising.

LL-37 is the only human cathelicidin-family host defense peptide and has been reported to interact with invading pathogens causing inflammation at various body sites. Recent studies showed high levels of LL-37 in the synovial-lining membrane of patients with rheumatoid arthritis, a common type of inflammatory arthritis. The present study aims to investigate the role of LL-37 on mechanisms associated with pathogenesis of inflammatory arthritis. The effects of LL-37 on the expression of proinflammatory cytokines, hyaluronan (HA) metabolism-related genes, cell death-related pathways, and cell invasion were investigated in SW982, a human synovial sarcoma cell line. Time-course measurements of proinflammatory cytokines and mediators showed that LL-37 significantly induced IL6 and IL17A mRNA levels at early time points (3–6 hr). HA-metabolism-related genes (i.e., HA synthase 2 ( HAS2 ), HAS3 , hyaluronidase 1 (HYAL1 ), HYAL2 , and CD44 ) were co-expressed in parallel. In combination, LL-37 and IL17A significantly enhanced PTGS2 , TNF , and HAS3 gene expression concomitantly with the elevation of their respective products, PGE2, TNF, and HA. Cell invasion rates and FN1 gene expression were also significantly enhanced. However, LL-37 alone or combined with IL17A did not affect cell mortality or cell cycle. Treatment of SW982 cells with both LL-37 and IL17A significantly enhanced IKK and p65 phosphorylation. These findings suggest that the chronic production of a high level of LL-37 may synchronize with its downstream proinflammatory cytokines, especially IL17A, contributing to the co-operative enhancement of pathogenesis mechanisms of inflammatory arthritis, such as high production of proinflammatory cytokines and mediators together with the activation of HA-metabolism-associated genes and cell invasion.

A novel coaxial surface dielectric barrier discharge (SDBD) non-thermal atmospheric pressure plasma device, driven by a 35.7-kHz DC pulse and adjustable by a pulse-width modulation, was developed in this study and preliminarily tested for its killing effects of a cancer cell type. This study was divided into three phases, namely, air phase, liquid phase, and cell phase. First, the electrical characteristics and emissions were examined. Two-beam UV-LED absorption spectroscopy was also newly developed to measure the absolute hydroxyl radical (OH⋅) density in the filamentary discharge. Then, the effects of energy doses and treatment durations on three types of liquids and on the colorectal adenocarcinoma cell, SW620, were examined. From Lissajous figures (Q–V plot), the developed SDBD possesses the maximum power density and energy dose of 0.33 ± 0.05 W/cm2 and 19.5 ± 3.00 J/cm2, respectively, when the voltage was set at 3.44 kV and the power at 115 mW. From two-beam UV-LED absorption spectroscopy results, the OH⋅ density increased by 0.32, 0.58, and 0.86 × 1019 m−3, with operational powers of 29, 58, and 115 mW, respectively, within 1-min treatment. In liquid phases, the plasma device can increase the concentrations of H2O2 and NO2− in a time-dependent manner. Finally, cell-phase studies, including the examination of the cell morphology, cell viability, and gene expression of the SW620 cell, show that the device can time-dependently induce the mortality of the SW620 cell, relevant to the up-regulation of the Bax/Bcl-2 expression ratio. Taken together, this novel SDBD plasma device shows potential as another alternative for cancer treatment, although further modification is required.

No abstract